Viewing Study NCT01313559

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:32 PM
Ignite Modification Date: 2026-01-07 @ 1:41 PM
Study NCT ID: NCT01313559
Status: TERMINATED
Last Update Posted: 2025-04-30
First Post: 2011-03-10
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Castrate Resistant Prostate Cancer View
None Chemotherapy Naive Prostate Cancer View
None Prostate Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Castrate Resistant View
None Chemotherapy Naive View
None Prostate Cancer View
None SOM230 View
None Everolimus View